Home / Stocks / Vaishali Pharma Limited
VAISHALI

Vaishali Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹7.1

Change

-0.08 (-1.11%)

Open

₹7.49

Prev. Close

₹7.18

Day High

₹7.49

Day Low

₹7.05

Volume Analysis

Traded

25,630

Delivered

17,743

Delivery %

69.23%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (3)

  • •Low return on equity (5.83%)
  • •Below-average fundamentals quality score (49/100)
  • •Low operating margin (3.9%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹7.81 ₹7.65 ₹7.37 ₹7.21 ₹6.93 ₹6.77 ₹6.49
Fibonacci ₹7.65 ₹7.48 ₹7.38 ₹7.21 ₹7.04 ₹6.94 ₹6.77
Camarilla ₹7.22 ₹7.18 ₹7.14 ₹7.21 ₹7.06 ₹7.02 ₹6.98

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-16.86%

1 Week

+0.71%

1 Month

-3.14%

3 Months

-11.14%

6 Months

+1.43%

1 Year

-26.73%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹6.08

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

5.86%

Net margin 3.7% × asset turnover 0.89x × equity multiplier 1.78x

Company Overview

Sector

Healthcare

Market Cap

₹95 Cr

P/E (TTM)

21.4

ROE

5.83%

Book Value

₹5.3

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Vaishali Pharma Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (5.83%); below-average fundamentals quality score (49/100).

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Valuation

57

Cash Flow

0

Corporate Governance

52

Momentum

45

Business Quality

39

Risk & Volatility

31

Liquidity

50

From Screener.in

  • −Promoter holding is low: 31.6%
  • −Earnings include an other income of Rs.3.57 Cr.
  • −Company has high debtors of 170 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Vaishali Pharma reports no deviation in Rs. 9.08 crore preferential issue proceeds for quarter ended 30 September 2026.

Appointment 05 Nov

Board appointed two independent directors on 5 Nov 2026 and deferred preferential issue proposal.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 33 25 27 23
Expenses + 32 23 27 21
Operating Profit 1 2 0 1
OPM % 4.16% 6.33% -0.74% 6.51%
Other Income + 1 1 1 1
Interest 0 1 1 0
Depreciation 0 0 0 0
Profit before tax 2 2 0 2
Tax % 28.31% 28.18% -61.11% 13.87%
Net Profit + 1 1 0 2
EPS in Rs 0 0 0 0
Raw PDF — — — —
YoY Sales growth — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2026 TTM
Sales + 109 108
Expenses + 105 104
Operating Profit 4 4
OPM % 3.8% 3.9%
Other Income + 4 4
Interest 2 2
Depreciation 1 1
Profit before tax 5 5
Tax % 25.0% —
Net Profit + 4 4
EPS in Rs 0 0
Dividend Payout % 0.0% —
Sales growth — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2026
Reserves 43
Borrowings + 19
Other Liabilities + 35
Total Liabilities 123
Fixed Assets + 2
CWIP 0
Investments 6
Other Assets + 116
Total Assets 123
Equity Capital 26

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2026
Cash from Operating Activity + 0
Cash from Investing Activity + -5
Cash from Financing Activity + 5
Net Cash Flow 0
Free Cash Flow 0
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 26.62% → 31.61%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 73.38% 73.68% 73.68% 73.67% 73.68% 73.68% 73.68% 73.68% 68.39% 68.39% 68.39% 68.39%
Promoters 26.62% 26.32% 26.32% 26.32% 26.32% 26.32% 26.32% 26.32% 31.61% 31.61% 31.61% 31.61%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Vaishali Pharma Limited (this stock) 95 21.4 1.33 5.83%
Alpa Laboratories Ltd 109 52.0 0.59 8.38%
Sunil Healthcare Ltd. 78 26.6 1.03 6.01%
Parnax Lab Ltd. 125 14.6 1.27 14.2%
Bal Pharma Ltd. 135 17.1 1.58 7.79%
Natural Capsules Limited 144 — 0.66 -9.45%
Mangalam Drug & Chem Ltd 45 — 0.51 -35.3%

Which Mutual Funds Hold Vaishali Pharma Limited?

Frequently Asked Questions about Vaishali Pharma Limited

Community Sentiment

What are other investors saying about Vaishali Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.